|
Efinaconazole (trade names Jublia or Clenafin) is a triazole antifungal. It is approved for use in Canada and the USA as a 10% topical solution for the treatment of onychomycosis (fungal infection of the nail). Efinaconazole acts as a 14α-demethylase inhibitor.〔(【引用サイトリンク】url = http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/203567s000lbl.pdf )〕 In two clinical trials 17.8% and 15.2% of patients using Efinaconazole were cured, compared to 3.3% and 5.5% of patients using a placebo.〔 Efinaconazole is not especially effective, but it is currently the best topical treatment available, with cure rates two or three times better than the next best topical treatment, ciclopirox. It is considered a reasonable options for patients with mild cases, or patients who can not take oral treatment.〔(【引用サイトリンク】url = http://www.podiatrytoday.com/blogged/closer-look-new-topical-option-onychomycosis )〕 In 2014, the U.S. Food and Drug Administration (FDA) approved the New Drug Application (NDA) for Jublia, the "first topical triazole approved for the treatment of onychomycosis of the toenails." According to Valeant Pharmaceuticals International Inc CEO J. Michael Pearson they acquired Jublia through their purchase of Dow Pharmaceutical Sciences in 2008.〔 ==See also== * Ciclopirox 抄文引用元・出典: フリー百科事典『 ウィキペディア(Wikipedia)』 ■ウィキペディアで「Efinaconazole」の詳細全文を読む スポンサード リンク
|